Personal information

Keywords

Cancer Immunology and Immunotherapy, Inflammatory Cell Death

Countries

China

Activities

Collapse all

Employment (4)

Peking-Tsinghua Center for Life Sciences: Beijing, CN

2022-07-20 to present | Principle Investigator
Employment
Source: Self-asserted source
Ying Zhang

Peking University: Beijing, CN

2022-07-20 to present | Principle Investigator (School of Life Sciences)
Employment
Source: Self-asserted source
Ying Zhang

Harvard Medical School: Boston, Massachusetts, US

2021-02-01 to 2022-06-30 | Instructor (Department of Pediatrics)
Employment
Source: Self-asserted source
Ying Zhang

Harvard Medical School and Boston Children's Hospital: Boston, Massachusetts, US

2016-11-01 to 2021-02-01 | Postdoctoral Fellow
Employment
Source: Self-asserted source
Ying Zhang

Education and qualifications (2)

University of Pennsylvania: Philadelphia, PA, US

2009-09-01 to 2016-08-20 | Ph.D. (School of Medicine)
Education
Source: Self-asserted source
Ying Zhang

Nankai University: Tianjin, CN

2005-09-01 to 2009-06-20 | Biological Sciences (School of Life Sciences)
Education
Source: Self-asserted source
Ying Zhang

Professional activities (2)

American Association of Immunologists: Md., Md., US

2015 to present
Service
Source: Self-asserted source
Ying Zhang

American Association for Cancer Research: PA, PA, US

2014 to present
Service
Source: Self-asserted source
Ying Zhang

Funding (3)

Gasdermin E-mediated pyroptosis in promoting antitumor immunity and cancer treatment

2020-02-02 to 2022-01-31 | Grant
National Cancer Institute (Bethesda, US)
URL: https://app.dimensions.ai/details/grant/grant.9560146
GRANT_NUMBER: K99CA255841
Source: Self-asserted source
Ying Zhang via DimensionsWizard

Enhancing Immunotherapy for Triple-Negative and HER2+ Breast Cancer Using EpCAM Aptamer-siRNA-Mediated Gene Knockdown

2019-02-01 to 2022-01-31 | Grant
Congressionally Directed Medical Research Programs (Frederick, US)
URL: https://app.dimensions.ai/details/grant/grant.8100841
GRANT_NUMBER:

W81XWH-19-1-0039
Source: Self-asserted source
Ying Zhang via DimensionsWizard
grade
Preferred source (of 2)‎

Enhancing Immunotherapy for Triple-Negative and HER2+ Breast Cancer Using EpCAM Aptamer-siRNA-Mediated Gene Knockdown

2018-06 to 2019-02 | Award
Cancer Research Institute (New York, US)
Source: Self-asserted source
Ying Zhang

Works (17)

Dying to survive: harnessing inflammatory cell death for better immunotherapy

Trends in Cancer
2025-04 | Journal article
DOI: 10.1016/j.trecan.2025.01.012
Contributors: Long Cheng; Yibo Wang; Ying Zhang
Source: check_circle
Crossref

Small-molecule GSDMD agonism in tumors stimulates antitumor immunity without toxicity

Cell
2024-10 | Journal article
DOI: 10.1016/j.cell.2024.08.007
Part of ISSN: 0092-8674
Contributors: Pietro Fontana; Gang Du; Ying Zhang; Haiwei Zhang; Setu M. Vora; Jun Jacob Hu; Ming Shi; Ahmet B. Tufan; Liam B. Healy; Shiyu Xia et al.
Source: Self-asserted source
Ying Zhang

Tumor editing suppresses innate and adaptive antitumor immunity and is reversed by inhibiting DNA methylation

Nature Immunology
2024-10 | Journal article
DOI: 10.1038/s41590-024-01932-8
Contributors: Ying Zhang; Pourya Naderi Yeganeh; Haiwei Zhang; Simon Yuan Wang; Zhouyihan Li; Bowen Gu; Dian-Jang Lee; Zhibin Zhang; Athanasios Ploumakis; Ming Shi et al.
Source: check_circle
Crossref

The NK cell receptor NKp46 recognizes ecto-calreticulin on ER-stressed cells

Nature
2023-04-13 | Journal article
DOI: 10.1038/s41586-023-05912-0
Contributors: Sumit Sen Santara; Dian-Jang Lee; Ângela Crespo; Jun Jacob Hu; Caitlin Walker; Xiyu Ma; Ying Zhang; Sourav Chowdhury; Karla F. Meza-Sosa; Mercedes Lewandrowski et al.
Source: check_circle
Crossref

Targeting stem-loop 1 of the SARS-CoV-2 5′ UTR to suppress viral translation and Nsp1 evasion

Proceedings of the National Academy of Sciences
2022-03 | Journal article
DOI: 10.1073/pnas.2117198119
Contributors: Setu M. Vora; Pietro Fontana; Tianyang Mao; Valerie Leger; Ying Zhang; Tian-Min Fu; Judy Lieberman; Lee Gehrke; Ming Shi; Longfei Wang et al.
Source: check_circle
Crossref

SPARCLE, a p53-induced lncRNA, controls apoptosis after genotoxic stress by promoting PARP-1 cleavage

Molecular Cell
2022-02 | Journal article
DOI: 10.1016/j.molcel.2022.01.001
Contributors: Karla F. Meza-Sosa; Rui Miao; Francisco Navarro; Zhibin Zhang; Ying Zhang; Jun Jacob Hu; Corrine Corrina R. Hartford; Xiao Ling Li; Gustavo Pedraza-Alva; Leonor Pérez-Martínez et al.
Source: check_circle
Crossref

Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown

Proceedings of the National Academy of Sciences
2021-03-02 | Journal article
DOI: 10.1073/pnas.2022830118
Contributors: Ying Zhang; Xuemei Xie; Pourya Naderi Yeganeh; Dian-Jang Lee; David Valle-Garcia; Karla F. Meza-Sosa; Caroline Junqueira; Jiayu Su; Hongbo R. Luo; Winston Hide et al.
Source: check_circle
Crossref

Lighting a Fire: Can We Harness Pyroptosis to Ignite Antitumor Immunity?

Cancer Immunology Research
2021-01-01 | Journal article
DOI: 10.1158/2326-6066.cir-20-0525
Part of ISSN: 2326-6066
Part of ISSN: 2326-6074
Contributors: Zhibin Zhang; Ying Zhang; Judy Lieberman; Ying Zhang
Source: Self-asserted source
Ying Zhang

FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation

Nature Immunology
2020-07 | Journal article
DOI: 10.1038/s41590-020-0669-6
Contributors: Jun Jacob Hu; Xing Liu; Shiyu Xia; Zhibin Zhang; Ying Zhang; Jingxia Zhao; Jianbin Ruan; Xuemei Luo; Xiwen Lou; Yang Bai et al.
Source: check_circle
Crossref

Gasdermin E suppresses tumour growth by activating anti-tumour immunity

Nature
2020-03-11 | Journal article
DOI: 10.1038/s41586-020-2071-9
Part of ISSN: 0028-0836
Part of ISSN: 1476-4687
Source: Self-asserted source
Ying Zhang

Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy.

Cancer cell
2017-09-01 | Journal article
DOI: 10.1016/j.ccell.2017.08.004
PMID: 28898698
PMC: PMC5751418
Source: Self-asserted source
Ying Zhang

Aging: T cell metabolism within tumors.

Aging
2016-06-01 | Journal article
DOI: 10.18632/aging.100979
PMID: 27282177
PMC: PMC4931823
Source: Self-asserted source
Ying Zhang

Depletion of FAP+ cells reduces immunosuppressive cells and improves metabolism and functions CD8+T cells within tumors.

Oncotarget
2016-04-01 | Journal article
DOI: 10.18632/oncotarget.7818
PMID: 26943036
PMC: PMC5029626
Source: Self-asserted source
Ying Zhang

Starved and Asphyxiated: How Can CD8(+) T Cells within a Tumor Microenvironment Prevent Tumor Progression.

Frontiers in immunology
2016-02-10 | Journal article
DOI: 10.3389/fimmu.2016.00032
PMID: 26904023
PMC: PMC4748049
Source: Self-asserted source
Ying Zhang

The effect of adjuvanting cancer vaccines with herpes simplex virus glycoprotein D on melanoma-driven CD8+ T cell exhaustion.

Journal of immunology (Baltimore, Md. : 1950)
2014-07-14 | Journal article
DOI: 10.4049/jimmunol.1302029
PMID: 25024391
PMC: PMC4254702
Source: Self-asserted source
Ying Zhang

TGF-β-associated miR-27a inhibits dendritic cell-mediated differentiation of Th1 and Th17 cells by TAB3, p38 MAPK, MAP2K4 and MAP2K7.

Genes and immunity
2012-10-04 | Journal article
DOI: 10.1038/gene.2012.45
PMID: 23034448
Source: Self-asserted source
Ying Zhang

Antigen presentation by dendritic cells in tumors is disrupted by altered metabolism that involves pyruvate kinase M2 and its interaction with SOCS3.

Cancer research
2009-12-08 | Journal article
DOI: 10.1158/0008-5472.can-09-2970
PMID: 19996282
Source: Self-asserted source
Ying Zhang
How many people are using ORCID?